CONMED Corporation (NASDAQ:CNMD) has been issued a 2 rating by the sell-side brokerage firms covering the stock. Basing the rating on a simplified scale where 1 represents a Buy and 5 represents a Sell, this is the average rating based on the 6 firms polled by Zacks Research. To determine the direction the stock sentiment is headed, it’s noted that the stock had a rating of 2 three months ago.

The sell-side brokers covering the equity also have issued projected stock price objectives on the company. The one year projections range from a high of $65 to the low of $51. The mean price target of all analysts taken into consideration by Zacks is $59.

Earnings at a Glance

Near term, Wall Street brokerage analysts are expecting CONMED Corporation (NASDAQ:CNMD) to report earnings of $0.43 per share for the fiscal quarter ending on 2015-06-30. This is the calculated earnings per share estimate from the 6 polled by Zacks. In taking a look further ahead three to five years, analysts have a long-term growth EPS estimate of $15. This number is the best estimate for sales and earnings over that time frame.

Stock holders will be watching when CONMED Corporation reports their next earnings results on 2015-07-22. Most recently the firm announced earnings per share of $0.42 for the quarter which ended on 2015-03-31. Compared to analyst expectations just before the announcement, the actual results were $0.01 away from that number, or a surprise factor of 2.44%.

CONMED Corporation (CONMED) is a medical technology company/ The Company emphasizes on surgical devices and equipment for minimally invasive procedures and monitoring. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The Company operates in five segments: CONMED Endoscopic Technologies, CONMED Endosurgery, CONMED Electrosurgery, CONMED Linvatec and CONMED Patient Care. The Company offers a range of devices and products for uses in arthroscopic surgery. The Company’s powered instruments product line includes the MPower battery system. The Company’s patient care product line includes a line of vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, electrocardiogram (ECG) electrodes and cables, cardiac defibrillation and pacing pads and blood pressure cuffs.

Related Articles

Back to top button